23-MULTI-62-BI-PMC (1438-0005): An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Rel

Grants and Contracts Details

StatusActive
Effective start/end date2/26/242/26/26

Funding

  • Boehringer-Ingelheim: $100,935.00